2-amino-6-anilino-purines and their use as medicaments

US6767906B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Patricia Imbach · Kaiseraugst, CH
• Hans-Georg Capraro · Rheinfelden, CH
• Jurg Zimmermann · Möhlin, CH
• Giorgio Caravatti · Allschwil, CH
• Pascal Furet · Basel, CH
• Wolfgang Brill · Schopfheim, DE

Key dates

• Filing date: Aug 10, 2001
• Grant date: Jul 27, 2004
• Expiry date: Aug 10, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application discloses 2-amino-6-anilino-purine derivatives of the formula I in whichq is 1-5, andR1 is&agr;) —S(═O)k—NR6R7, in which k is 1 or 2, wherein under the proviso that R6 and R7 cannot be simultaneously hydrogen&agr;1) R6, R7 can be identical or different from one another and represent an aliphatic, carbocyclic, heterocyclic, carbocyclic-aliphatic or heterocyclic-aliphatic radical; hydrogen or lower aliphatic acyl; or&agr;2) R6 and R7 together are an alkylene or alkenylene radical having from 3 up to and including 9 C atoms, in which 1-3 C atoms can be replaced by oxygen, sulfur or nitrogen,&bgr;) N-(aryl lower alkyl)carbamoyl, or&ggr;) a radical of the formula —NH—S(═O)i—R8, in which i is 1 or 2, R8 is an aliphatic, carbocyclic or heterocyclic radical; or&dgr;) a radical of the formula —NH—C(═O)—R9, and the other variable substituents are as defined herein. The inventive compounds inhibit p34cdc2/cyclin Bcdc13 kinase and protein tyrosine kinase pp60c-src and can be used for treatment of hyperproliferative diseases, for example tumour diseases, and diseases which respond to in…